Susan Wojcicki, the late CEO of YouTube, had a message for the world just weeks before she passed away in August: “Lung ...

Early cancer detection often marks the difference between successful treatment and grave outcomes. Understanding warning ...

Fatigue that does not improve with rest can be an early sign of cancer. The National Cancer Institute notes that cancer-related fatigue is different from the tiredness that healthy people feel. It's ...

1 “The prognosis for patients diagnosed with biliary tract cancer is poor, as very few treatment options exist ... occurring ...

Cancer natives, this week brings a blend of familial warmth and potential stressors. While you'll be tending to loved ones' ...

Christopher Burge was on 'Jeopardy!' on Nov. 19 and shared he has Stage 4 colon cancer at 34. He spoke with TODAY.com about ...

Zanidatamab is a bispecific antibody that binds to 2 non-overlapping extracellular epitopes of the HER2 receptor.

Currently, chemotherapy remains a common treatment for biliary tract cancers, which have a limited survival rate.

The bispecific antibody zanidatamab is now the first HER2-targeted therapy approved for patients with locally advanced or metastatic HER2-positive biliary tract cancer.

Zanidatamab is the first agent approved specifically for advanced, HER2-positive second-line biliary tract cancer.